Stryker Co. (NYSE:SYK) Shares Acquired by Creative Planning

Creative Planning boosted its position in shares of Stryker Co. (NYSE:SYK) by 0.9% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 79,875 shares of the medical technology company’s stock after purchasing an additional 716 shares during the period. Creative Planning’s holdings in Stryker were worth $27,178,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in SYK. Aviso Wealth Management acquired a new stake in shares of Stryker during the second quarter valued at about $203,000. Ascent Group LLC grew its stake in Stryker by 4.4% during the 2nd quarter. Ascent Group LLC now owns 3,790 shares of the medical technology company’s stock valued at $1,290,000 after purchasing an additional 159 shares in the last quarter. Driehaus Capital Management LLC grew its stake in Stryker by 73.8% during the 2nd quarter. Driehaus Capital Management LLC now owns 1,107 shares of the medical technology company’s stock valued at $377,000 after purchasing an additional 470 shares in the last quarter. Oliver Lagore Vanvalin Investment Group increased its holdings in Stryker by 14.4% during the 2nd quarter. Oliver Lagore Vanvalin Investment Group now owns 2,041 shares of the medical technology company’s stock worth $694,000 after purchasing an additional 257 shares during the last quarter. Finally, Scientech Research LLC raised its position in shares of Stryker by 46.3% in the 2nd quarter. Scientech Research LLC now owns 1,527 shares of the medical technology company’s stock valued at $520,000 after purchasing an additional 483 shares in the last quarter. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Stryker Trading Down 0.3 %

Shares of NYSE:SYK opened at $360.27 on Monday. Stryker Co. has a fifty-two week low of $249.98 and a fifty-two week high of $374.63. The company has a quick ratio of 0.95, a current ratio of 1.68 and a debt-to-equity ratio of 0.51. The company has a market cap of $137.29 billion, a PE ratio of 41.13, a P/E/G ratio of 2.78 and a beta of 0.91. The company’s 50-day moving average price is $347.92 and its 200 day moving average price is $342.96.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Tuesday, July 30th. The medical technology company reported $2.81 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.79 by $0.02. The business had revenue of $5.42 billion during the quarter, compared to analyst estimates of $5.40 billion. Stryker had a return on equity of 22.89% and a net margin of 16.12%. The business’s revenue for the quarter was up 8.5% compared to the same quarter last year. During the same period in the prior year, the company posted $2.54 EPS. Sell-side analysts anticipate that Stryker Co. will post 12 earnings per share for the current year.

Stryker Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, October 31st. Investors of record on Monday, September 30th will be given a $0.80 dividend. The ex-dividend date is Monday, September 30th. This represents a $3.20 dividend on an annualized basis and a yield of 0.89%. Stryker’s dividend payout ratio is presently 36.53%.

Insider Buying and Selling at Stryker

In related news, VP M Kathryn Fink sold 2,121 shares of the firm’s stock in a transaction that occurred on Friday, September 13th. The shares were sold at an average price of $370.00, for a total transaction of $784,770.00. Following the transaction, the vice president now owns 10,042 shares in the company, valued at $3,715,540. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other news, VP M Kathryn Fink sold 2,121 shares of Stryker stock in a transaction on Friday, September 13th. The stock was sold at an average price of $370.00, for a total transaction of $784,770.00. Following the transaction, the vice president now directly owns 10,042 shares in the company, valued at approximately $3,715,540. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Ronda E. Stryker sold 190,000 shares of the business’s stock in a transaction on Tuesday, August 6th. The stock was sold at an average price of $323.46, for a total value of $61,457,400.00. Following the completion of the sale, the director now directly owns 3,316,608 shares in the company, valued at approximately $1,072,790,023.68. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 220,068 shares of company stock valued at $71,811,372. Company insiders own 5.90% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the stock. Stifel Nicolaus dropped their price target on shares of Stryker from $375.00 to $365.00 and set a “buy” rating for the company in a research note on Wednesday, July 31st. UBS Group upped their target price on shares of Stryker from $351.00 to $366.00 and gave the company a “neutral” rating in a research note on Wednesday, July 31st. Wolfe Research began coverage on shares of Stryker in a research report on Tuesday, September 10th. They set an “outperform” rating and a $405.00 price target on the stock. Needham & Company LLC upped their price objective on Stryker from $392.00 to $393.00 and gave the company a “buy” rating in a research note on Thursday, August 1st. Finally, StockNews.com downgraded Stryker from a “buy” rating to a “hold” rating in a report on Monday, September 16th. Five equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. Based on data from MarketBeat.com, Stryker currently has an average rating of “Moderate Buy” and an average target price of $378.58.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.